Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Lung
Published in: Lung 5/2008

01-10-2008

Increased Pleural Soluble Fas Ligand (sFasL) Levels in Tuberculosis Pleurisy and Its Relation with T-helper Type 1 Cytokines

Authors: Ferah Budak, Esra Kunt Uzaslan, Şengül Cangür, Güher Göral, Haluk Barbaros Oral

Published in: Lung | Issue 5/2008

Login to get access

Abstract

Tuberculosis (TB) pleurisy is accepted to be the best model for evaluating the local protective cellular immune response to Mycobacterium tuberculosis (MTB) since it can be spontaneously self-cured. Therefore, we aimed to evaluate the involvement of cytokines and the soluble apoptosis-modulating factors sFas and sFasL in local protective cellular immunity to MTB. Pleural fluid samples were collected from 35 patients with TB pleurisy, 39 patients with malignant pleurisy, and 14 patients with non-TB nonmalignant (n-TB n-M) pleurisy and were evaluated for the levels of several cytokines, soluble Fas (sFas), and sFas ligand (sFasL) by using ELISA. The levels of IFN-γ, IL-12p40, IL-18, IL-8, and sFasL in TB pleurisy were significantly higher in comparison to those in the malignant pleurisy and n-TB n-M pleurisy groups. In addition, pleural sFasL levels were increased and positively correlated with IFN-γ and IL-18 levels in TB patients. In conclusion, this study demonstrates that Th1-type-specific cellular immunity is responsible for protective immunity in TB and suggests that Fas-mediated apoptosis may be at least a part of protective immunity to tuberculosis and could be regulated by type 1 T-cell response. IFN-γ and sFasL levels can be used as diagnostic markers for differing TB pleurisy from other pleurisies.
Literature
1.
2.
Prabha CJK, Matsa RP, Das SD (2003) Role of TNF-alpha in host immune response in tuberculous pleuritis. Curr Sci 85:639–642
3.
Morehead RS (1998) Tuberculosis of the pleura. South Med J 91:630–636PubMed
4.
Abbas AK, Murphy KM, Sher A (1996) Functional diversity of helper T lymphocytes. Nature 383:787–793PubMedCrossRef
5.
Infante-Duarte C, Kamradt T (1999) Th1/Th2 balance in infection. Springer Semin Immunopathol 21:317–338PubMedCrossRef
6.
Fujiwara H, Tsuyuguchi I (1986) Frequency of tuberculin-reactive T-lymphocytes in pleural fluid and blood from patients with tuberculous pleurisy. Chest 89:530–532PubMedCrossRef
7.
Barnes PF, Fong SJ, Brennan PJ, Twomey PE, Mazumder A, Modlin RL (1990) Local production of tumor necrosis factor and IFN-gamma in tuberculous pleuritis. J Immunol 145:149–154PubMed
8.
Wu SH, Chu JJ, Chiang CD (2001) Increased soluble Fas ligand concentration in tuberculous pleural effusion. J Formos Med Assoc 100:32–34PubMed
9.
Fayyazi A, Eichmeyer B, Soruri A, Schweyer S, Herms J, Schwarz P, Radzun HJ (2000) Apoptosis of macrophages and T cells in tuberculosis associated caseous necrosis. J Pathol 191:417–425PubMedCrossRef
10.
11.
Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759–1762PubMedCrossRef
12.
Wang PS, Chen YM, Hsieh YL, Yu CF, Tsai CM, Perng RP (2002) Pleural effusion and serum soluble fas-ligand levels are elevated in different clinical conditions. Lung 180:25–32PubMedCrossRef
13.
Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr (1972) Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 77:507–513PubMed
14.
Jamil B, Shahid F, Hasan Z, Nasir N, Razzaki T, Dawood G, Hussain R (2007) Interferon gamma/IL10 ratio defines the disease severity in pulmonary and extra pulmonary tuberculosis. Tuberculosis (Edinb) 87:279–287CrossRef
15.
Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, Schreiber R, Mak TW, Bloom BR (1995) Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561–572PubMedCrossRef
16.
Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM (1993) Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 178:2243–2247PubMedCrossRef
17.
Kindler V, Sappino AP (1991) The beneficial effects of localized tumor necrosis factor production in BCG infection. Behring Inst Mitt 88:120–124PubMed
18.
Ameixa C, Friedland JS (2002) Interleukin-8 secretion from Mycobacterium tuberculosis-infected monocytes is regulated by protein tyrosine kinases but not by ERK1/2 or p38 mitogen-activated protein kinases. Infect Immun 70:4743–4746PubMedCrossRef
19.
Collins HL, Kaufmann SH (2001) The many faces of host responses to tuberculosis. Immunology 103:1–9PubMedCrossRef
20.
Ahn HJ, Maruo S, Tomura M, Mu J, Hamaoka T, Nakanishi K, Clark S, Kurimoto M, Okamura H, Fujiwara H (1997) A mechanism underlying synergy between IL-12 and IFN-gamma-inducing factor in enhanced production of IFN-gamma. J Immunol 159:2125–2131PubMed
21.
Robinson D, Shibuya K, Mui A, Zonin F, Murphy E, Sana T, Hartley SB, Menon S, Kastelein R, Bazan F, O’Garra A (1997) IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB. Immunity 7:571–581PubMedCrossRef
22.
Yao NS, Chen YM, Perng RP, Whang-Peng J (2002) Additive effect of interleukin-12 and interleukin-18 on the T-helper cell pathway of malignant pleural effusion. Lung 180:15–24PubMedCrossRef
23.
Murray PJ, Wang L, Onufryk C, Tepper RI, Young RA (1997) T cell-derived IL-10 antagonizes macrophage function in mycobacterial infection. J Immunol 158:315–321PubMed
24.
Gazzinelli RT, Oswald IP, Hieny S, James SL, Sher A (1992) The microbicidal activity of interferon-gamma-treated macrophages against Trypanosoma cruzi involves an L-arginine-dependent, nitrogen oxide-mediated mechanism inhibitable by interleukin-10 and transforming growth factor-beta. Eur J Immunol 22:2501–2506PubMedCrossRef
25.
Balcewicz-Sablinska MK, Keane J, Kornfeld H, Remold HG (1998) Pathogenic Mycobacterium tuberculosis evades apoptosis of host macrophages by release of TNF-R2, resulting in inactivation of TNF-alpha. J Immunol 161:2636–2641PubMed
26.
Gesser B, Leffers H, Jinquan T, Vestergaard C, Kirstein N, Sindet-Pedersen S, Jensen SL, Thestrup-Pedersen K, Larsen CG (1997) Identification of functional domains on human interleukin 10. Proc Natl Acad Sci USA 94:14620–14625PubMedCrossRef
27.
Akdis CA, Joss A, Akdis M, Faith A, Blaser K (2000) A molecular basis for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding. FASEB J 14:1666–1668PubMed
28.
Cohen SB, Crawley JB, Kahan MC, Feldmann M, Foxwell BM (1997) Interleukin-10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl-2. Immunology 92:1–5PubMedCrossRef
29.
Bogdan C, Vodovotz Y, Paik J, Xie QW, Nathan C (1994) Mechanism of suppression of nitric oxide synthase expression by interleukin-4 in primary mouse macrophages. J Leukoc Biol 55:227–233PubMed
30.
Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, Dolganov GM, Sherman DR, Schoolnik GK (2003) Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 198:705–713PubMedCrossRef
31.
Essner R, Rhoades K, McBride WH, Morton DL, Economou JS (1989) IL-4 down-regulates IL-1 and TNF gene expression in human monocytes. J Immunol 142:3857–3861PubMed
32.
Joyce DA, Steer JH (1996) IL-4, IL-10 and IFN-gamma have distinct, but interacting, effects on differentiation-induced changes in TNF-alpha and TNF receptor release by cultured human monocytes. Cytokine 8:49–57PubMedCrossRef
33.
Brodbeck WG, Shive MS, Colton E, Ziats NP, Anderson JM (2002) Interleukin-4 inhibits tumor necrosis factor-alpha-induced and spontaneous apoptosis of biomaterial-adherent macrophages. J Lab Clin Med 139:90–100PubMedCrossRef
34.
Rook GA, Dheda K, Zumla A (2005) Immune responses to tuberculosis in developing countries: implications for new vaccines. Nat Rev Immunol 5:661–667PubMedCrossRef
35.
36.
Hernandez-Pando R, Aguilar D, Hernandez ML, Orozco H, Rook G (2004) Pulmonary tuberculosis in BALB/c mice with non-functional IL-4 genes: changes in the inflammatory effects of TNF-alpha and in the regulation of fibrosis. Eur J Immunol 34:174–183PubMedCrossRef
37.
Bonecini-Almeida MG, Ho JL, Boechat N, Huard RC, Chitale S, Doo H, Geng J, Rego L, Lazzarini LC, Kritski AL, Johnson WD Jr, McCaffrey TA, Silva JR (2004) Down-modulation of lung immune responses by interleukin-10 and transforming growth factor beta (TGF-beta) and analysis of TGF-beta receptors I and II in active tuberculosis. Infect Immun 72:2628–2634PubMedCrossRef
38.
Rook GA, Lowrie DB, Hernandez-Pando R (2007) Immunotherapeutics for tuberculosis in experimental animals: is there a common pathway activated by effective protocols? J Infect Dis 196:191–198PubMedCrossRef
39.
Villegas MV, Labrada LA, Saravia NG (2000) Evaluation of polymerase chain reaction, adenosine deaminase, and interferon-gamma in pleural fluid for the differential diagnosis of pleural tuberculosis. Chest 118:1355–1364PubMedCrossRef
40.
Hua CC, Chang LC, Chen YC, Chang SC (1999) Proinflammatory cytokines and fibrinolytic enzymes in tuberculous and malignant pleural effusions. Chest 116:1292–1296PubMedCrossRef
41.
Ogawa K, Koga H, Hirakata Y, Tomono K, Tashiro T, Kohno S (1997) Differential diagnosis of tuberculous pleurisy by measurement of cytokine concentrations in pleural effusion. Tuber Lung Dis 78:29–34PubMedCrossRef
42.
Zhang M, Gately MK, Wang E, Gong J, Wolf SF, Lu S, Modlin RL, Barnes PF (1994) Interleukin 12 at the site of disease in tuberculosis. J Clin Invest 93:1733–1739PubMedCrossRef
43.
Vankayalapati R, Wizel B, Weis SE, Samten B, Girard WM, Barnes PF (2000) Production of interleukin-18 in human tuberculosis. J Infect Dis 182:234–239PubMedCrossRef
44.
Yamada Y, Nakamura A, Hosoda M, Kato T, Asano T, Tonegawa K, Itoh M (2001) Cytokines in pleural liquid for diagnosis of tuberculous pleurisy. Respir Med 95:577–581PubMedCrossRef
45.
Dlugovitzky D, Rateni L, Torres-Morales A, Ruiz-Silva J, Pinesky R, Canosa B, Molteni O, Bottasso O (1997) Levels of interleukin-8 in tuberculous pleurisy and the profile of immunocompetent cells in pleural and peripheral compartments. Immunol Lett 55:35–39PubMedCrossRef
46.
Ottenhoff TH, Haanen JB, Geluk A, Mutis T, Ab BK, Thole JE, van Schooten WC, van den Elsen PJ, de Vries RR (1991) Regulation of mycobacterial heat-shock protein-reactive T cells by HLA class II molecules: lessons from leprosy. Immunol Rev 121:171–191PubMedCrossRef
47.
Hancock GE, Cohn ZA, Kaplan G (1989) The generation of antigen-specific, major histocompatibility complex-restricted cytotoxic T lymphocytes of the CD4+ phenotype. Enhancement by the cutaneous administration of interleukin 2. J Exp Med 169:909–919PubMedCrossRef
48.
Ottenhoff TH, Mutis T (1990) Specific killing of cytotoxic T cells and antigen-presenting cells by CD4+ cytotoxic T cell clones. A novel potentially immunoregulatory T-T cell interaction in man. J Exp Med 171:2011–2024PubMedCrossRef
49.
Boom WH, Wallis RS, Chervenak KA (1991) Human Mycobacterium tuberculosis-reactive CD4+ T-cell clones: heterogeneity in antigen recognition, cytokine production, and cytotoxicity for mononuclear phagocytes. Infect Immun 59:2737–2743PubMed
50.
Oddo M, Renno T, Attinger A, Bakker T, MacDonald HR, Meylan PR (1998) Fas ligand-induced apoptosis of infected human macrophages reduces the viability of intracellular Mycobacterium tuberculosis. J Immunol 160:5448–5454PubMed
51.
Silva CL, Lowrie DB (2000) Identification and characterization of murine cytotoxic T cells that kill Mycobacterium tuberculosis. Infect Immun 68:3269–3274PubMedCrossRef
52.
Lewinsohn DM, Bement TT, Xu J, Lynch DH, Grabstein KH, Reed SG, Alderson MR (1998) Human purified protein derivative-specific CD4+ T cells use both CD95-dependent and CD95-independent cytolytic mechanisms. J Immunol 160:2374–2379PubMed
53.
Mustafa T, Phyu S, Nilsen R, Bjune G, Jonsson R (1999) Increased expression of Fas ligand on Mycobacterium tuberculosis-infected macrophages: a potential novel mechanism of immune evasion by Mycobacterium tuberculosis? Inflammation 23:507–521PubMed
54.
Li B, Bassiri H, Rossman MD, Kramer P, Eyuboglu AF, Torres M, Sada E, Imir T, Carding SR (1998) Involvement of the Fas/Fas ligand pathway in activation-induced cell death of mycobacteria-reactive human gamma delta T cells: a mechanism for the loss of gamma delta T cells in patients with pulmonary tuberculosis. J Immunol 161:1558–1567PubMed
55.
Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S (1997) Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 186:2045–2050PubMedCrossRef
56.
Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, Tschopp J (1998) Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 187:1205–1213PubMedCrossRef
57.
Mitani K, Nishioka Y, Yamabe K, Ogawa H, Miki T, Yanagawa H, Sone S (2003) Soluble Fas in malignant pleural effusion and its expression in lung cancer cells. Cancer Sci 94:302–307PubMedCrossRef
58.
Boselli D, Losana G, Bernabei P, Bosisio D, Drysdale P, Kiessling R, Gaston JS, Lammas D, Casanova JL, Kumararatne DS, Novelli F (2007) IFN-gamma regulates Fas ligand expression in human CD4+ T lymphocytes and controls their anti-mycobacterial cytotoxic functions. Eur J Immunol 37:2196–2204PubMedCrossRef
Metadata
Title
Increased Pleural Soluble Fas Ligand (sFasL) Levels in Tuberculosis Pleurisy and Its Relation with T-helper Type 1 Cytokines
Authors
Ferah Budak
Esra Kunt Uzaslan
Şengül Cangür
Güher Göral
Haluk Barbaros Oral
Publication date
01-10-2008
Publisher
Springer-Verlag
Published in
Lung / Issue 5/2008
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-008-9107-5

Other articles of this Issue 5/2008

Lung 5/2008 Go to the issue

OriginalPaper

Squamous Cell Carcinoma Antigen in Lung Cancer and Nonmalignant Respiratory Diseases

OriginalPaper

Diagnostic Performance of 18F-FDG PET/CT for Lymph Node Staging in Patients with Operable Non-small-cell Lung Cancer and Inflammatory Lung Disease

OriginalPaper

Ventilatory Capacity and Its Utilisation During Exercise

Report

A Qualitative Study of Individuals at Risk for or Who Have Chronic Obstructive Pulmonary Disease: What Do They Understand About Their Disease?

OriginalPaper

Tracheobronchopathia Osteochondroplastica: Presentation of Ten Cases and Review of the Literature

OriginalPaper

Patterns of Healthcare Utilization by COPD Severity: A Pilot Study
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits